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ABSTRACT 
Aggregation and deposition of misfolded amyloid  (A) peptide in the brain is 
central to Alzheimer’s disease (AD). Oligomeric, protofibrillar and fibrillar forms of A are 
believed to be neurotoxic and cause neurodegeneration in AD, but the toxicity mechanisms 
are not well understood and may involve A-interacting molecular partners. In a previous 
study, we identified potential A42 protofibrillar-binding proteins in serum and cerebrospinal 
fluid (CSF) using an engineered version of A42 (A42CC) that forms protofibrils, but not 
fibrils. Here we studied binding of proteins to A42 fibrils in AD and non-AD CSF and 
compared these with protofibrillar A42CC-binding partners. A42 fibrils sequestered 2.4-fold 
more proteins than A42CC protofibrils. Proteins with selective binding to fibrillar aggregates 
with low nanomolar affinity were identified. We also found that protofibrillar and fibrillar 
A-binding proteins represent distinct functional categories. A42CC protofibrils triggered 
interactions with proteins involved in catalytic activities, like transferases and 
oxidoreductases, whilst A42 fibrils were more likely involved in binding to proteoglycans, 
growth factors and neuron-associated proteins, e.g., neurexin-1, -2 and -3. Interestingly, 10 
brain-enriched proteins were identified among the fibril-binding proteins, whilst protofibril-
extracted proteins had more general expression patterns. Both types of A aggregates bound 
several extracellular proteins. Additionally, we list a set of CSF proteins that might have 
potential to discriminate between AD and non-AD CSF samples. The results may be of 
relevance both for biomarker studies and for studies of A-related toxicity mechanisms.  
 




Protein misfolding is associated with a broad range of human diseases [1]. 
Alzheimer’s disease (AD), the most common cause of dementia affecting more than 40 
million individuals worldwide, is the most well-known protein misfolding disease [2]. 
Misfolded tau and amyloid  (A) peptide accumulation within and around the nerve cells 
are the major pathological hallmarks of AD. A peptides are proteolytic cleavage products of 
the amyloid precursor protein (APP). An imbalance between production and clearance of 
A results in misfolding and the subsequent formation of morphological and conformational 
distinct species ranging from A dimers to insoluble fibrils [3, 4]. Although much attention 
has been given to A in the field of AD research, the exact roles of various structural 
assemblies of A in AD pathogenesis remain to be elucidated. A peptides may be present in 
both non-AD and AD brains, indicating that A alone might not be sufficient to cause AD 
[5]. Today, an important hypothesis is that interaction of A with certain molecular partners 
may contribute to the development of AD [5-7]. 
Both protofibrillar and fibrillar form of A are neurotoxic (reviewed in [1]) and the 
toxicity might be due to interaction of A with other proteins, including membrane proteins 
and intracellular and extracellular components [8-10]. Several proteins, e.g., -1 
antichymotrypsin, apolipoprotein E and J, complement components, collagen, heparin sulfate 
proteoglycan and serum amyloid P, have been reported to colocalize with A [8, 11-14], and 
may contribute to A-related toxicity due to loss of function of the interacting proteins [15] 
or gain of toxic function of A [16]. Moreover, interaction of A with other proteins may 
activate tissue reactions of relevance to neurodegeneration [9], e.g., microglial and astrocytic 
activation in the plaque-affected brain tissue [17]. A-interacting partners may target A for 
internalization into the cell or sequestration in the extracellular matrix, instead of clearance of 
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A into the blood. Several studies have been conducted to explore A-binding partners [11, 
18] and some A-binding partners alongside with other aggregation inhibitor compounds are 
also tested for their ability to modulate A aggregation (reviewed in [8, 19]). However, our 
knowledge about which proteins in body fluids, e.g., cerebrospinal fluid (CSF, the biofluid 
that is most similar to the brain interstitial fluid where Aβ aggregates), associate with A is 
limited. Such knowledge would provide new potential molecules that may be targeted to 
prevent amyloid formation and its associated toxicity.  
We have recently investigated the binding of serum and CSF proteins to Aβ 
protofibrils formed by an Aβ variant called Aβ42CC [20]. Protofibrils formed by wild-type 
Aβ peptide are unstable and propagate rapidly into mature fibrils [21]. Thus, the wild-type 
protofibril is not optimal in studies of protofibrillar interaction with human fluid proteins. 
Protofibrils formed by Aβ42CC variant are stable and do not convert into mature fibrils [22], 
and the protofibrils are indistinguishable in structure and cell toxicity from the protofibrillar 
aggregates generated by wild-type Aβ42 [23, 24]. We have identified approximately 100 
proteins in serum and CSF that bind to Aβ42CC protofibrils, including known Aβ-binding 
amyloid proteins, proteins involved in complement system and hemostasis, as well as in lipid 
transport and metabolism. The aims of this study were: to investigate which proteins in CSF 
associate to mature Aβ42 fibrils and to examine if such proteins are different from those found 
to associate with Aβ42CC protofibrils; to analyze the molecular function and cellular location 
of fibrillar Aβ-targeted proteins and to explore if protein-binding is changed upon Aβ 
aggregation from protofibrils to fibrils.  
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MATERIALS AND METHODS 
Cerebrospinal fluid samples 
Samples were from patients who sought medical advice because of cognitive 
impairment. Patients were designated as AD or non-AD according to CSF biomarker levels 
that are >90% sensitive and specific for AD, as previously described [25]. Demographics are 
summarized in Table 1. The ethics committee at the University of Gothenburg approved the 
study. 
Peptide production and aggregate formation  
A42CC and A42 peptides were produced by co-expression with an Affibody 
molecule, and the purification was performed as described previously [22, 23, 26]. The 
peptides were separated from the Affibody by denaturation in 7 M guanidine hydrochloride 
(GdnHCl) followed by an immobilized metal affinity chromatography (IMAC) purification 
under denaturing condition.  
A42CC protofibrils were obtained by dialysis of the peptide solution against 20 mM 
Na-phosphate, pH 7.4, 50 mM NaCl with 1 mM EDTA overnight followed by a second 
dialysis for 7 h in the same buffer without EDTA. The sample was heated to 60 °C for 10 min 
[23]. 
Wild-type A42 peptide was loaded onto a Superdex 75 16/600 column (GE 
Healthcare) equilibrated with 20 mM Na-phosphate, pH 10.5, 150 mM NaCl to change pH 
(from 8 to 10.5) as well as to confirm monomeric species. To produce fibrils, monomeric 
Aβ42 was spun down at 17,000 ×g using Heraeus Pico 17 centrifuge (Thermo Scientific) for 
10 minutes to pellet any existing insoluble aggregates. The supernatant was transferred to a 
new tube. Fibrils formation was induced by adjusting the pH of the alkaline (pH ~10.5) 
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solution to pH 7.4 (with 1 M HCl) in 20 mM Na-phosphate, 50 mM NaCl [21]. Fibrils (25 
µM assay concentration) were allowed to form at 37 °C for 96 h without agitation [27].  
Microscopy analysis  
Twenty µL Aβ42CC protofibril or Aβ42 fibril solutions were applied onto formvar-
coated copper grids and negatively stained with 2% uranyl acetate in 50% ethanol for 1 min. 
Air-dried samples were analyzed at 75 kV in a Hitachi 7100 transmission electron 
microscopy (TEM) and images were obtained with a Gatan 832 Orius SC1000. 
Protein pull-down assay  
The assay was performed as previously described [20]. Briefly, 100 µg ligands 
(Aβ42CC protofibrils or Aβ42 fibrils) were incubated with 5 mg Tosyl-activated Dynabeads 
M-280 beads (Invitrogen) in 0.1 M Na-phosphate pH 7.4 at 37 °C overnight for covalent 
binding. The beads were then incubated for 1 h in PBS buffer at pH 7.4 with 0.5% Tween-20 
to block free binding sites. Beads incubated with 5 µg/mL glycine were used as control.  
Aβ42CC protofibril and Aβ42 fibril coupled beads (0.5 mg) and control beads (0.5 mg) were 
incubated with 200 µL CSF at 37 °C for 1 h. After incubation, beads were washed three times 
in PBS buffer at pH 7.4 with 0.1% Tween-20. Proteins bound to Aβ42CC protofibrils, Aβ42 
fibrils or control beads were eluted in 62.5 mM Tris-HCl, 25% glycerol, 2% SDS by heating 
at 70 °C for 10 min. 
Mass spectrometry analysis 
The mass spectrometry analysis was carried out as described by Rahman et al. [20]. 
In brief, proteins were reduced in 45 mM dithiothreitol, alkylated in 100 mM iodoacetamide 
and in-solution (proteins bound to Aβ42 fibrils) or in-gel (proteins bound to Aβ42CC 
protofibrils) digested by 50 ng trypsin per µg of proteins. Thereafter, trypsinized peptides 
were desalted on a ZipTip C18 column, dried and resolved in 0.1% formic acid. The peptides 
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were separated in reversed-phase on a C18-column with a 60 minutes gradient and electro-
sprayed on-line to a Q Exactive Plus mass spectrometer (Thermo Finnigan). Tandem mass 
spectrometry was performed applying higher energy collisional dissociation (HCD). Peptide 
database searches were performed using the Mascot algorithm towards human proteins in the 
SwissProt database (released Nov-2016). 
Surface plasmon resonance analysis 
Surface plasmon resonance (SPR) analysis was performed on a Biacore X100 
instrument (GE Healthcare). The Aβ42CC protofibril and Aβ42 fibril (30 µg/mL) were 
immobilized onto a CM5-sensor chip (GE Healthcare) as described previously [28]. A stable 
final immobilization level of ca. 3000 response unit (RU) was achieved.  
Recombinant human proteins, agrin (cat. 6624-AG-050), dickkopf-related protein 3 (cat. 
1118-DK-050), neurocan (cat. 6508-NC-050), osteopontin (cat. 1433-OP-CF) and SPARC-
like protein (cat. 2728-SL-050), were purchased from R&D Systems, USA. Lyophilized 
proteins were dissolved in HBS-EP (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% 
Tween-20, pH 7.4) buffer. The analytes were diluted to concentrations of 10 nM, 20 nM, 40 
nM and 60 nM in HBS-EP and injected over the immobilized Aβ42CC protofibrils and Aβ42 
fibrils surface for 180 s. The dissociation phase was monitored for 600 s in HBS-EP buffer. 
The analysis was implemented as a multiple cycle setup with a flow rate of 30 μL/min at 25 
°C. The surface was regenerated after each injection of analyte with 15 mM NaOH which 
completely remove bound analyte without disturbing the surface [20, 28]. Collected SPR data 
was evaluated using the Biacore X100 Evaluation 2.0.1 software.  
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RESULTS 
Characterization of A aggregates 
Fibrillar appearances of A42CC protofibrils and A42 fibrils were confirmed by TEM 
after negative staining of samples with 2% uranyl acetate. In accordance with typical 
protofibrils morphology, the A42CC protofibrils appeared as spherical shapes with an 
average diameter of 5 nm [22] (Fig. 1a). Also, the preparation contained some smooth 
curvature. The A42 fibrils appeared with an average diameter of 7-9 nm (Fig. 1b) as 
expected for amyloid fibrils [1, 29]. 
Binding of CSF proteins to A42 fibrils 
Fibrils of A42 were ligated on Tosyl-activated Dynabeads M-280 and incubated with 
CSF samples. The complex was then washed several times to remove unbound proteins. 
Proteins bound to A42 fibrils were eluted and analyzed by LC-MS to identify which proteins 
that had been captured by A42 fibrils. Through the LC-MS analysis, we identified a total of 
202 proteins that bound to A42 fibrils from the 11 CSF samples analyzed (Supplementary 
Table S1). The number of identified proteins in individual CSF samples ranged from 53 to 
152. The number of identified proteins did not correlate with total proteins content of the 
individual samples or sex. However, a positive correlation between age and identified protein 
number was detected in samples from patients diagnosed with AD (Supplementary Table S2). 
As controls, beads coated with glycine and incubated with CSF were used. We have 
previously tested a set of different controls, including tryptophan and non-disease related 
Sup35 nanofibers [20]. In the present investigation, we only used glycine as control. One 
non-AD and one AD sample were incubated with glycine coated beads and analyzed by LC-
MS. As expected, very few proteins, 3 from the non-AD and 2 from AD patient sample, were 
found to bind to the control (Supplementary Table S1). Likewise, the peptide abundance 
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indices (PAI) [30] verify that the binding to control is much lower compared to binding to 
A42 fibrils. The PAI values of three proteins bound to control are 0.08, 0.08 (±0.04) and 
0.09 (±0.03) for apoE, clusterin and serum albumin, respectively; while PAI values for these 
proteins bound to fibril are 0.8 (±0.07), 0.4 (±0.04) and 0.37 (±0.09).  
Protofibrillar and fibrillar binding partners 
One major objective with this study was to identify A42 fibril-binding proteins in 
CSF and compare these with A42CC protofibril-binding partners [20]. We tested the same 
set of samples (except one AD sample that was excluded due to limited amount), maintained 
the same conditions for capturing assay and LC-MS characterization as for the previous 
study. Additionally, to verify the accuracy of the experimental conditions, two CSF samples 
were tested for binding to A42CC protofibrils, and analyzed by LC-MS. The result was in 
agreement with previous analysis. Three new proteins were identified, and the total number 
of identified proteins was less compared to previous results, approximately 27 proteins were 
identified compared to 38 proteins in the earlier study. However, it cannot be ruled out that 
there was some technical variability in the LC-MS analyses carried out at the two different 
occasions. Furthermore, the A42 fibril-binding protein list was further corrected by 
subtracting proteins with molecular weight below 20 and above 250 kDa. The rational for this 
subtraction was, for identification of A42CC protofibril-binding proteins, the pull-down 
fraction was loaded on to an SDS-PAGE and proteins migrating between 20-250 kDa were 
recovered, digested and subjected to LC-MS analysis, while in this study the whole pull-
down fraction was analyzed through LC-MS. The subtracted proteins are listed in 
Supplementary Table S3.  
We found that A42 fibrils attract more proteins (ca. 2.4-fold) than A42CC 
protofibrils (Fig. 1c). Thus, binding of proteins to A is enhanced upon aggregation from 
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protofibrils to fibrils. Proteins identified to bind to A42CC protofibrils and A42 fibrils 
shared some similarities, approximately 20% common proteins (Supplementary Table S4). 
However, the list of A42 fibril-binding proteins contained a substantial number of proteins, 
66% CSF proteins, that did not bind to A42CC protofibrils. Hence, we have called these 
A42 fibril-specific proteins (Supplementary Table S5). Some of these proteins, including 
agrin, extracellular matrix protein-1, neurocan and SPARC-like protein 1 have been reported 
to bind to A42 fibrillar aggregates [10]. Interestingly, many of the A42 fibril-specific 
proteins, e.g., amyloid-like protein 1, dickkopf-related protein 3, major prion protein, fibulin-
5, and proSAAS were identified to bind to fibrils formed by non-disease related protein 
Sup35 [20], indicating that these proteins have more specificity toward fibrils than 
protofibrils. Furthermore, a number of amyloid-related proteins, including transthyretin and 
prion protein were identified to bind to fibrils which were not observed for A42CC 
protofibrils (Supplementary Table S5 and supplementary information S1 in reference [20]). 
Validation of conformation-dependent binding  
We used an SPR biosensor-based assay to further validate protein-binding to A42 
aggregates, and also verify A42 conformation-dependent binding of CSF proteins. For more 
detailed binding studies, by SPR, we selected agrin, dickkopf-related protein 3, neurocan, 
osteopontin and SPARC-like protein 1, since they were all found in this study to bind to A42 
fibrils but not to A42CC protofibrils, and they are also close associated to AD biology 
(discussed below). We also tested apolipoprotein E4 (apoE4) which was found to bind to 
both A42CC protofibrils and A42 fibrils, thus serving as positive control. For this 
experiment, we immobilized A42CC protofibrils or A42 fibrils on a Biacore CM5 sensor 
chip using standard amine coupling chemistry. Binding of human proteins to the immobilized 
surface was recorded. The SPR kinetics confirmed that all tested proteins, except osteopontin, 
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bound well to A42 fibrils immobilized surface, but did not bind to A42CC protofibrils 
immobilized surface, as expected (Fig. 2 and supplementary figure S1). Although it seemed 
that the neurocan showed some affinity to A42CC protofibrils at high concentration (60 nM, 
5.7 RU, cyan line in PF surface in Fig. 2), binding kinetics on this data set could not be 
determined. The experiment was repeated with higher neurocan concentration (125 to 500 
nM), but no significant improvement of binding kinetics was observed (data not shown). 
ApoE4 (positive control) was found to bind to both A42CC protofibrils and A42 fibrils (Fig. 
2, bottom panel). Data from binding to A42 fibrils (all tested proteins) and to A42CC 
protofibrils (apo E4) fitted well to a heterogeneous ligand-binding model with global kinetics 
fitting but local maximum response [28]. The equilibrium dissociation constant (KD) for 
binding to A42 fibrils was determined to be KD = 3.5 nM for agrin, KD = 26.2 nM for 
dickkopf-related protein 3, KD = 11.7 nM for neurocan; and KD = 6.2 nM for the SPARC-like 
protein 1. The positive control, apoE4, bound to A42CC protofibrils and A42 fibrils with a 
KD of 5.7 nM and 0.3 nM, respectively. The association and dissociation rates and the 
equilibrium dissociation constant of all tested proteins are found in Supplementary Table S6.  
Gene ontology annotation 
Gene ontology (GO) analysis was performed to annotate and compare annotated 
categories of protofibril- and fibril-binding proteins. The annotation was performed using the 
PANTHER classification system (http://pantherdb.org/, database version 12.0, released 2017-
07-10) [31].  
Almost half of the proteins (46.6%) that were identified as protofibril binders were 
classified as proteins with catalytic activity, and about one-third of the proteins (30.9%) were 
categorized as protein with binding properties. In contrast, the major portion (49%) of the 
fibril-binding proteins were annotated as proteins with binding properties, and a quarter of 
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the proteins (24%) were classified as proteins with catalytic activity (Fig. 3a). The other 
notable difference was that 12.9% of the fibril-binding proteins were related to structural 
proteins, while this proportion was only 7.4% for protofibril-bound proteins. A small 
proportion (2%) of the fibril-binding proteins was annotated as being involved in signal 
transduction, but this functional group was not seen in protofibril-binding proteins.  
As shown in Fig. 3b, more than half of the proteins identified to bind to both 
protofibrils and fibrils were annotated as extracellular region proteins (44.6%) and 
extracellular matrix proteins (11.9%). The brain extracellular components are annotated to be 
involved in networking or have a structural and functional role [32]. The other half of the 
identified proteins was annotated as macromolecular complex proteins (9.2%), plasma 
membrane (8.7%), organelle (11.5%) and intracellular associated proteins (12.6%). Notably, 
2% of the fibril-binding proteins were annotated to be located in nerve synapses but the 
protofibril-binding proteins were not presented in the synapses. 
Identification of brain-enriched proteins 
The Human Protein Atlas (HPA) database [33] (database version 16) was utilized to 
search for brain-enriched proteins among the A42CC protofibril and A42 fibril binding 
proteins. The brain tissue-enriched proteins (n=415, at least five-fold higher mRNA levels in 
a particular tissue as compared to all other tissues) database was downloaded from the HPA 
website (https://www.proteinatlas.org). Based on HPA tissue-enriched proteins database, a 
total of 10 brain-enriched proteins were identified among the A42 fibril-binding proteins 
(Fig. 4a). On the contrary, the A42CC protofibril-binding proteins did not represent any 
proteins enriched in the brain. Interestingly, the brain-enriched proteins were found to be 
more abundant in AD compared to non-AD samples (Fig. 4b), according to peptide 
abundance indices [30].  
 13 
Novel proteins  
We identified several proteins that readily bound to A42 fibrils from at least 2 AD 
samples, but no proteins bound from non-AD samples, and vice versa. Proteins that were 
identified in a number of non-AD samples, and only in one or two AD samples were 
categorized as ‘abundant in non-AD CSF’ and the opposite identification pattern was 
categorized as ‘abundant in AD CSF’ (Fig. 5). Neurexins (including neurexin-1, neurexin-2, 
neurexin-2 beta and neurexin-3), glypican-1, plexin-B2 and glutamate receptor 4 were found 
to bind to A42 fibrils from AD samples only. There were also examples of proteins like 
calreticulin, neurofilament heavy polypeptide and protein AMBP that were only identified to 
bind to A42 fibrils from non-AD samples.  
Agrin and decorin are extracellular matrix protein that belongs to the proteoglycan 
family. These proteins were found to be abundant in AD CSF (agrin was identified in 4 and 
decorin was identified in 5 out of 6 samples) than in non-AD CSF (agrin was identified in 1 
and decorin was identified in 2 out of 5 samples). Another interesting protein in the AD 
abundant protein list was growth arrest-specific protein 6 (Gas6), this protein has 
neurotrophic and neuroinflammatory functions [34]. Neurexins are transmembrane proteins, 
expressed at the presynaptic side of the neuron. Neurexins seemed to be more abundant in 
AD than non-AD CSF (Fig. 5). However, proteins identified to readily bind to A42 fibrils 
from AD CSF were correlated with A and Alzheimer’s disease.  
Of non-AD abundant proteins, calreticulin was identified to bind to fibrils from three 
(out of six) non-AD samples, and from none of five AD samples (Fig. 5). Complement-
related proteins, e.g., complement C1r subcomponent, complement factor H and complement 
factor H-related protein 1 were identified in at least five out of six non-AD samples, whilst 
these proteins were identified in only one or two (complement factor H was identified in two 
samples) out of five AD samples. Protein AMBP (alpha-1-microglobulin/bikunin, an 
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abundant serum glycoprotein) was identified in four non-AD samples but was absent in the 




A frequently discussed hypothesis is that the interaction of A with certain molecular 
partners may contribute to the development of AD [5-7, 29]. In this work, we have identified 
and compared A42 fibril-binding proteins in CSF samples from AD vs. non-AD patients 
using a pull-down assay coupled to mass spectrometry. A couple of hundred proteins from 
CSF were identified to bind to A42 fibrils. Then, we compared A42 fibril-binding proteins 
with the protein bound to A42CC protofibrils (a mimic of wild-type protofibrils), which 
were recently identified by us [20]. Protein binding was further validated using an SPR-based 
biosensor assay. Several studies have been performed to identify A-interacting partners in 
serum [11] and A precursor protein (APP)-interacting partners in brain extract [18], and 
some of the proteins identified in our study have been reported to bind A or APP 
previously, e.g., agrin [36, 37], glypican-1 [38], apoE, apoJ, and serum amyloid P [11]. 
However, these studies were either performed in buffers or included only a few biologically 
relevant samples whereas our study was performed on many CSF samples. We choose to 
work with CSF since this body fluid is the most similar to the interstitial fluid where A 
aggregates. Moreover, CSF offers an environment that is close to the brain environment thus 
the best body fluid to study brain proteins. Furthermore, CSF A42 level reflect the amyloid 
load in AD brain accurately [39]. Brain tissue extracts could potentially provide additional 
interaction partners to A aggregates, which should be an interesting topic for future studies.  
A substantial number of proteins was identified to bind to A42 fibrils in CSF 
samples, and the number of interaction partners is much larger (ca. 2.4-fold) compared to 
A42CC protofibril-binding proteins. One can think of several factors that could play critical 
role for binding more proteins to A42 fibrils and for the difference in protein binding profiles 
of A42 fibrils compared to A42CC protofibrils (see below). Such biophysical determinant 
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differences could be the surface charge potential, tertiary structure of the binding surface, 
surface modification such as N- or O-glycosylation of the target protein, or pure structural 
sterical differences between the bound proteins. However, a possible explanation for the 
greater number of proteins identified as fibril binders could be that the protein ligand could 
have access to more binding sites onto the long fibrils surface compared to protofibrils that 
are much smaller in length and might be more compactly oriented onto the Dynabeads. 
Likewise, the protofibril and fibril could represent completely different binding surfaces. 
Indeed, distinct sets of protein were identified for both types of aggregates which is in 
agreements with earlier data [10].  The structural differences between in vitro protofibril and 
fibril are well characterized. However, a recent study showed that fibrils isolated from two 
different AD brain are structurally and pathologically different [40], and such in vivo 
structurally different fibrils could potentially have distinct set of binding partners which 
might also reflect on disease progression. Furthermore, protofibrils and fibrils could 
potentially also recognize different molecular surface on closely related proteins or peptides. 
For instance, complement C1q subcomponent subunit A, B, and C were identified to bind to 
protofibril but not to fibril, while their associate complement C1r and C1s subcomponent did 
not bind to protofibril but fibril. A set of proteins is identified as specific for fibrils, and some 
of these have previously been found to bind to non-disease related Sup35 fibril [20], which 
has a similar structure to the A fibril [41], suggesting that the distinct set of fibril-binding 
proteins may be due to conformation-specific interaction. Furthermore, our SPR data also 
suggests that the protein binding to A is directed by the conformation of the A aggregates. 
However, further structural studies of A aggregates and other binding proteins is required to 
get insight into the structural basis of the binding. 
The gene ontology annotation [31] of the protofibril- and fibril-binding proteins 
revealed that they form distinct functional classes. A42CC protofibrils trigger interaction 
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networks with enzymes (47% protofibril-binding proteins were annotated to possess catalytic 
activity), whereas A42 fibrils are more likely to bind proteins such as lipid, nucleic acid and 
calcium ion binding (49% fibril-binding proteins were annotated to binding activity). 
However, this picture might not be entirely accurate due to the notable differences between 
the number of protofibril- and fibril-binding partners (relatively small number of proteins was 
identified for protofibrils compared to fibrils).  The GO terms cellular component analysis 
showed that more than half of the A aggregate-binding proteins are extracellular region and 
matrix proteins. In the brain, the extracellular components play important roles in 
networking, structure, and function, and the distribution of extracellular component in the 
brain is region-dependent [32]. Moreover, the extracellular proteins have been reported to be 
more abundant in CSF compared to serum [42]. Thus, it is not unexpected that A would 
bind to a large degree of extracellular proteins in CSF, which is frequently in communication 
with the extracellular space in the brain [35]. 
We explored differences in expression profiles of protofibrillar and fibrillar 
interaction partners in CSF. Ten brain-enriched proteins were identified as selective 
interaction partners to Aβ fibrils and some of them, e.g., neurosecretory protein VGF, have 
previously been described as candidate biomarkers for AD [43].  
Several proteins identified in our study may have potential for AD biomarkers. We 
found that some proteins were more prone to bind A42 fibrils from AD samples than from 
non-AD samples. Agrin, an extracellular matrix heparin sulphate proteoglycan expressed in 
neurons in different brain areas [36], is one such protein that was identified as particularly 
abundant in AD samples. The protein is often reported to be present in senile plaque and also 
reported to accelerate A fibril formation [37]. Our finding resonates well with an earlier 
study showing increased levels of agrin in seven samples from AD patients compared with 
non-AD controls (n=12) [44]. Moreover, a recent study showed that agrin concentration 
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correlates with the age of the AD patient [45], a result that is also corroborated by our 
findings; we identified agrin in four samples, where the patient age was 59-75 years, whilst 
the age of the patient in which agrin was not found was 54 year. Furthermore, our kinetics 
data showed that agrin has high affinity (KD= 0.3 nM) to A42 fibrils. Like agrin, decorin was 
also found abundant in AD CSF samples. Notably, both of these proteins belong to the 
proteoglycan family. Evidence suggests that decorin is colocalized with A in a transgenic 
mice model of AD [46], and in brains of patients diagnosed with AD [47]. Neurexins were 
also found to be more abundant in CSF samples from AD patients than non-AD. They have 
been reported to bind APP, and more interestingly, processing of neurexin e.g., neurexin-3 
isoform is similar to APP processing by α- and γ-secretases [48]. Gas6 was also found 
abundant in AD samples. Recently, Sainaghi and co-workers [34] measured an increased 
Gas6 concentration in CSF samples from AD patients (n= 63) compared to samples from 
non-AD controls (n=67). They also suggested that upregulation of CSF Gas6 might be a 
defensive response against AD progression. Proteins that are more readily bind to A42 fibrils 
from non-AD CSF samples, thus abundant in non-AD CSF include calreticulin, complement 
factor H, and protein AMBP. Calreticulin is a major calcium-binding protein found in smooth 
muscle sarcoplasmic reticulum and non-muscle endoplasmic reticulum. The protein has been 
identified as an APP-interacting partner and binds to the γ-secretase cleavage site within 
APP which leads to reduced level A42 production in cell culture [49]. Moreover, reduced 
levels of calreticulin were measured in serum of patients with AD [50], and may thus be 
negatively correlated with AD, which potentially could help explain the abundance of 
calreticulin in non-AD samples. 
A is one of the major players in the pathogenesis of AD, but the pathways it 
activates to initiate neurodegeneration remain elusive. In this study, we present A-binding 
protein partners in CSF from AD and non-AD patients. A comparison between protofibrillar 
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and fibrillar partners was also carried out. Our results demonstrate that protofibrillar and 
fibrillar A interact with a broad range of CSF proteins, and that the binding profile is 
conformation-dependent since distinct protein sets were identified for each type of aggregate. 
The identified proteins also present distinct functionality when comparing protofibrillar and 
fibrillar A-interacting partners. Taken together, our results pinpoint a number of Aβ-
interacting partners that should be included in future studies on biomarkers as well as in 
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TABLE  
Table 1. Demographic information of CSF samples.  
 non-AD AD 
n 6 5 
Age (mean ±SD) 71 (±7.1) a 63 (±9.6)  
Gender M/F 1/3 b 2/3 
CSF Tau (mean ±SD, ng/L) 263 (± 146) 789 (± 104) 
CSF Aβ1-42 (mean ±SD, ng/L) 809 (± 254) 468 (± 152) 
CSF Phospho tau (mean ±SD, ng/L) 40 (± 18) 95 (± 12) 
a Calculated from four samples 




Fig. 1. TEM micrograph showing the assembly of A42CC protofibrils (a) and A42 fibrils 
(b). The scale bar is 200 nm. (c) A comparison of the number of proteins identified to bind to 
A42CC protofibrils with proteins identified to bind to A42 fibrils in individual CSF 




Fig. 2. Representative Biacore sensorgrams showing interactions of recombinant human 
proteins with A42 fibril- and A42CC protofibril-immobilized surfaces (F and PF surfaces, 
respectively). The protein concentrations used are 10 (red), 20 (green), 40 (blue) and 60 
(cyan) nM, respectively. The dashed lines represent experimental data. Data collected from 
the interaction with the two surfaces were fitted to a heterogeneous ligand model. The fitted 





Fig. 3. Pie graphs representing the gene ontology terms molecular function (a) and cellular 
component (b) annotation of proteins bound to A42CC protofibrils and A42 fibrils in CSF.  
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Fig. 4. (a) CSF proteins identified to bind to fibrils represent a set of brain-enriched proteins. 
(b) Peptide abundance indices of the brain-enriched proteins showed that the proteins are 




Fig. 5. A subset of CSF proteins that were found more prone to bind A42 fibrils either from 
AD or non-AD samples. Proteins that were identified in a number of AD CSF samples and 
only in one or in two non-AD CSF samples are shown as abundant in AD CSF and the 
opposite identification pattern are indicated as abundant in non-AD CSF.  
 
 
 
